



## Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant *KIT* D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

### SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: Crenolanib targets native leukemia cells *ex vivo*.** Comparison of sensitivity profiles of a mutant-FLT3 ITD and mutant-KIT D816V native leukemia patient sample in response to crenolanib.



**Supplementary Figure 2: Sensitivity of crenolanib with regard to culture conditions.** Ba/F3 FLT3 ITD cells were cultured in medium supplemented with 10% or 0,5% FBS and dose dilution assays using crenolanib were set up.